Citadel Advisors’s DA32 Life Science Tech Acquisition Corp DALS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-584,130
Closed -$5.99M – 15578
2023
Q2
$5.99M Sell
584,130
-143,192
-20% -$1.46M ﹤0.01% 3363
2023
Q1
$7.36M Buy
727,322
+5,862
+0.8% +$59K ﹤0.01% 3208
2022
Q4
$7.21M Buy
721,460
+425
+0.1% +$4.18K ﹤0.01% 3283
2022
Q3
$6.99M Buy
721,035
+94
+0% +$914 ﹤0.01% 3322
2022
Q2
$6.99M Buy
720,941
+125,000
+21% +$1.22M ﹤0.01% 3210
2022
Q1
$5.81M Buy
595,941
+2
+0% +$19 ﹤0.01% 3887
2021
Q4
$5.85M Sell
595,939
-15,978
-3% -$157K ﹤0.01% 4030
2021
Q3
$6.02M Buy
+611,917
New +$6.05M ﹤0.01% 3957

Citadel Advisors's DALS Position: Q3 2023 in Review

Citadel Advisors sold out of DA32 Life Science Tech Acquisition Corp (DALS) in Q3 2023, closing a stake of 584,130 shares — an estimated $5.99M sold.

Citadel Advisors first reported a position in DALS in Q3 2021 and held it in 8 quarters. The position peaked at $7.36M in Q1 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

  • Citadel Advisors reported no remaining DA32 Life Science Tech Acquisition Corp position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 584,130 DA32 Life Science Tech Acquisition Corp shares in Q3 2023, an estimated $5.99M.
  • Citadel Advisors first reported a position in DA32 Life Science Tech Acquisition Corp in Q3 2021 and held it in 8 quarters.
  • Citadel Advisors's DA32 Life Science Tech Acquisition Corp position peaked at $7.36M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.